• USA
    • GER
    • CHI
    • PT(BR)
    • U.K.

Risk Reduction Solutions for
Pharmaceutical, Life Sciences & Healthcare

  • USA
    • GER
    • CHI
    • PT(BR)
    • U.K.
  • Resources
    • FAQs
    • Quality Certificates
    • White Papers
    • Bioquell QuAD Data Portal
    • Training Portal
    • Material Safety Data Sheets
  • News & Events
  • Company
    • About Us
    • Company Locations
    • Distributors
    • Careers
    • Investors
  • Pharmaceuticals & Life Sciences
    • Our Technology for Life Sciences
    • Why Bioquell Technology?
    • Systems for Life Sciences
    • Rapid Bio Decontamination Service
    • Validation
  • Healthcare
    • Why Bioquell Technology?
    • The Bioquell Process
    • Bioquell Compared to UV
    • Vaporized vs Aerosolized
    • Systems for Healthcare
    • Services for Healthcare
  • Rapid Bio Decontamination Service
    • For Life Sciences
    • For Healthcare
    • Applications
      • Remediation Needs
      • Emergency Response
      • Disaster Recovery Plan
      • Commissioning
      • End of Campaign and Facility Restart
      • Lab and Research Spaces
      • Hospital Related Contamination Events
  • Qube Isolator
  • Contact
    • Pharmaceuticals & Life Sciences
      • Our Technology for Life Sciences
      • Why Bioquell Technology?
      • Systems for Life Sciences
      • Rapid Bio Decontamination Service
      • Validation
    • Healthcare
      • Why Bioquell Technology?
      • The Bioquell Process
      • Bioquell Compared to UV
      • Vaporized vs Aerosolized
      • Systems for Healthcare
      • Services for Healthcare
    • Rapid Bio Decontamination Service
      • For Life Sciences
      • For Healthcare
      • Applications
        • Remediation Needs
        • Emergency Response
        • Disaster Recovery Plan
        • Commissioning
        • End of Campaign and Facility Restart
        • Lab and Research Spaces
        • Hospital Related Contamination Events
    • Qube Isolator
    • Contact

Bioquell welcomes clarification of biocide regulations by HSE

October 2016

Leading Biodecontamination experts Bioquell warmly welcomes the latest publication by the HSE highlighting the timescale for hydrogen peroxide-based biocides to be compliant.

The HSE Biocides e-Bulletin 22 September 2016 is entitled ‘Active Substance Approval Reminder’ and summarises all of the key dates for the evaluation of hydrogen peroxide in Product Types 1, 2, 3, 4, 5 and 6 under the EU Biocides Regulation 528/2012 (EU BPR).

They confirm that hydrogen peroxide will be approved on 1 February 2017 for use in biocidal products placed on the EU market. All affected companies are reminded that they must apply for UK product authorisation by 1 February 2017 in order to keep their biocidal products on the UK market after the active substance approval date, 1 February 2017.

John Chewins, Bioquell’s Director, Scientific & Regulatory Affairs said, “Biocidal products containing this active substance will therefore need to obtain EU BPR authorisation if they are to remain on the market. Bioquell has already made all the appropriate steps to ensure our market leading product will continue to be on the market going forwards, helping our customers eliminate pathogens and control bioburden.”

The HSE Biocides e-Bulletin 22 September 2016 – Active Substance Approval Reminder can be found here https://content.govdelivery.com/accounts/UKHSE/bulletins/165c362

Sales and Technical Support & General Inquiries: +1 215 682 0225

702 Electronic Drive, Suite 200, Horsham, PA 19044

solutions@bioquell.com

  • © Bioquell Inc. 2019 All Rights Reserved
  • Privacy Policy
  • Terms of Use
Download PDF